Projecting future drug expenditures in U.S. Nonfederal hospitals and clinics-2013

American Journal of Health-System Pharmacy

Volumn 70, Issue 6, 2013, Pages 525-539

  Hoffman, James M ^a   Li, Edward ^b   Doloresco, Fred ^c,d   Matusiak, Linda ^e   Hunkler, Robert J ^e   Shah, Nilay D ^f   Vermeulen, Lee C ^g,h   Schumock, Glen T ^i,j  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF NEW ENGLAND   (United States)

^c School of Pharmacy and Pharmaceutical Sciences Buffalo   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e IQVIA   (United States)

^f MAYO CLINIC   (United States)

^g University of Wisconsin Health   (United States)

^h UNIVERSITY OF WISCONSIN MADISON   (United States)

ⁱ Department of Pharmacy Practice ^*  (United States)

^j UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ARIPIPRAZOLE; ATORVASTATIN; BENDAMUSTINE; BEVACIZUMAB; BORTEZOMIB; CETUXIMAB; CHICKENPOX VACCINE; CLOPIDOGREL; DENOSUMAB; DULOXETINE; ESOMEPRAZOLE; ETANERCEPT; FLUTICASONE PROPIONATE PLUS SALMETEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; GLATIRAMER; INFLIXIMAB; INSULIN GLARGINE; LANTUS SOLOSTAR; MONTELUKAST; OXALIPLATIN; PEMETREXED; PNEUMOCOCCUS VACCINE; QUETIAPINE; RANIBIZUMAB; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; ROSUVASTATIN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARICELLA ZOSTER VACCINE; ZOLEDRONIC ACID;

ARTICLE; DRUG APPROVAL; DRUG COST; DRUG UTILIZATION; HEALTH CARE UTILIZATION; HOSPITAL; HUMAN; ONCOLOGY; PRESCRIPTION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; TREND STUDY; UNITED STATES;

EID: 84875472981     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp120759     Document Type: Article

References (52)

1. Keehan SP, Cuckler GA, Sisko AM et al. National health expenditure projections: modest annual growth until coverage expands and economic growth accelerates. Health Aff. 2012; 31:1600-12.
2. Hoffman JM, Li E, Doloresco F et al. Projecting future drug expenditures-2012. Am J Health-Syst Pharm. 2012; 69:405-21.
3. IMS Health National Sales Perspectives. Analysis conducted by the authors. Analysis conducted November 2012.
4. IMS Health. The Uniform System of Classification (USC). www.imshealth.com/deployedfiles/ims/Global/Content/Insights/ Health%20Services%20Research%20Network/USC-Classification-Process-2011.pdf (accessed 2013 Jan 14).
5. Medco Health. Estimated dates of possible first-time generics/Rx-to-OTC market entry. https://host1.medcohealth.com/art/.../anticipatedfirsttime- generics.pdf (accessed 2012 Nov 24).
6. Food and Drug Administration. Drugs@ FDA. www.accessdata.fda.gov/scripts/ cder/drugsatfda/index.cfm (accessed 2012 Nov 22).
7. Santarus. Santarus announces FDA extension of UCERIS new drug application target action date to January 16, 2013. http://ir.santarus.com/releasedetail. cfm?releaseid=700255(accessed 2012 Nov 27).
8. NuPathe. FDA accepts NuPathe's migraine patch NDA resubmission for filing. http://ir.nupathe.com/press-releases/fda-accepts-nupathe-s-migraine- patchnda-resubmiss-nasdaq-path-0914651 (accessed 2012 Nov 27).
9. Impax Pharmaceuticals. Impax Pharmaceuticals announces extension of Rytary FDA review date to January 21, 2013. http://investors.impaxlabs.com/ Media-Center/Press-Releases/Press-Release-Details/2012/Impax-Pharmaceuticals- Announces-Extensionof-RytaryTM-FDA-Review-Date-to-January-21-20131131423/ default.aspx(accessed 2012 Nov 27).
10. Hyperion Therapeutics. Hyperion Therapeutics announces extension of action date for Ravicti NDA to January 23, 2013. http://investors.hyperiontx. com/releasedetail.cfm?ReleaseID=704867 (accessed 2012 Nov 27).
11. Sucampo Pharmaceuticals. U.S. Food and Drug Administration grants priority review status to AMITIZA® (lubiprostone) submission seeking approval for treatment of opioid-induced constipation. http://phx.corporate-ir. net/External.File?item=UGFyZW50SUQ9MTU0NjIxfENoaWxkSUQ9LTF8VHlwZT0z&t= 1(accessed 2012 Nov 27).
12. Furiex Pharmaceuticals. Furiex confirms Takeda's resubmissions of alogliptin and the fixed-dose combination alogliptin and pioglitazone NDAs to the U.S. FDA. http://investor.furiex.com/releasedetail.cfm?ReleaseID=696211 (accessed 2012 Nov 27).
13. Genzyme. FDA advisory committee recommends KYNAMRO for homozygous familial hypercholesterolemia. www.businesswire.com/news/genzyme/20121018006758/ en (accessed 2012 Nov 27).
14. Hemispherx Biopharma. FDA accepts complete response submission regarding the Ampligen new drug application for chronic fatigue syndrome. www.hemispherx.net/content/investor/default.asp?goto=738 (accessed 2012 Nov 27).
15. Genentech. ImmunoGen Inc. announces FDA has granted priority review status to the trastuzumab emtansine (TDM1) marketing application. http://investor.immunogen.com/releasedetail.cfm?ReleaseID=719165 (accessed 2012 Nov 27).
16. Bristol-Myers Squibb Company and Pfizer. FDA acknowledges receipt of resubmission of the ELIQUIS® (apixaban) new drug application to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. http://news.bms.com/press-release/rdnews/fda-acknowledges-receipt- resubmission-eliquis-apixaban-new-drugapplication-re&t=634842758218606633 (accessed 2012 Nov 27).
17. A.P. Pharma. A.P. Pharma announces PDUFA action date for APF530 new drug application resubmission. www.appharma.com/PDFs/10-16-12-APF530-NDA-Acceptance. pdf (accessed 2012 Nov 27).
18. Raptor Pharmaceutical Corp. Raptor Pharmaceutical announces FDA acceptance of new drug application for RP103 for the potential treatment of nephropathic cystinosis. http://ir.raptorpharma.com/releasedetail.cfm?ReleaseID= 682926(accessed 2012 Nov 27).
19. Titan Pharmaceuticals. Titan Pharmaceuticals announces submission of new drug application for probuphine for the treatment of opioid dependence. www.titanpharm.com/press/2012/121029-press-rel-titan-nda-submission.htm (accessed 2012 Nov 27).
20. Navidea Biopharmaceuticals. Navidea Biopharmaceuticals announces PDUFA goal date for Lymphoseek new drug application resubmission. http://ir.navidea. com/phoenix.zhtml?c=68527&p=irolnewsArticle&ID=1758296&highlight= (accessed 2012 Nov 27).
21. GSK and Theravance. GSK and Theravance announce FDA acceptance of FF/VI new drug application (NDA) submission in the US for COPD. http://investor. theravance.com/releasedetail.cfm?ReleaseID=709460 (accessed 2012 Nov 27).
22. Depomed. Depomed announces Serada NDA acceptance and FDA advisory committee meeting. http://investor.depomedinc.com/phoenix.zhtml?c=97276&p= irol-newsArticle&ID=1745141&highlight= (accessed 2012 Nov 27).
23. Delcath Systems. Delcath announces FDA accepts new drug application for its proprietary chemosaturation system with melphalan hydrochloride. www.delcath.com/news-events/news/article/reuters/1745070/(accessed 2012 Nov 27).
24. Forest Laboratories. Forest Laboratories submits new drug application for levomilnacipran for the treatment of major depressive disorder. http://investor.frx.com/press-release/business-developmentnews/ forest-laboratories-submitsnew-drug-application-levomilnaci (accessed 2012 Nov 27).
25. MAP Pharmaceuticals. MAP Pharmaceuticals resubmits new drug application to FDA for LEVADEX orally inhaled migraine drug. http://ir.mappharma.com/ releasedetail.cfm?ReleaseID=713682 (accessed 2012 Nov 27).
26. Salix Pharmaceuticals. FDA action on crofelemer NDA anticipated by end of 1Q2013. www.salix.com/news-media/news/index/fda-continues-review-ofcrofelemer- new-drug-applicationbeyond-pdufa-goal-date-of-september-5-2012.aspx (accessed 2012 Nov 27).
27. AVEO Oncology and Astellas Pharma. AVEO and Astellas announce submission of new drug application for tivozanib for the treatment of advanced renal cell carcinoma. http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol- newsArticle&ID=1739376&highlight (accessed 2012 Nov 27).
28. Carpenter D, Zucker EJ, Avorn J. Drugreview deadlines and safety problems. N Engl J Med. 2008; 358:1354-61.
29. Greenwood Village (CO): Truven Health Analytics Inc. http://www.redbook. com/redbook/online/(accessed 2012 Nov 19).
30. Pollack A. Sanofi halves price of cancer drug Zaltrap after Sloan-Kettering rejection. www.nytimes.com/2012/11/09/business/sanofi-halves- price-of-drugafter-sloan-kettering-balks-at-payingit.html?-r=0 (accessed 2013 Jan 14).
31. Van Cutsem E, Tabernero J, Lakomy R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a Phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatinbased regimen. J Clin Oncol. 2012; 30:3499-506.
32. Baselga J, Cortés J, Kim SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012; 366:109-19.
33. Downing NS, Ross JS, Jackevicius CA et al. Avoidance of generic competition by Abbott Laboratories' fenofibrate franchise. Arch Intern Med. 2012; 172:724-30.
34. Husten L. Another one bites the dust: Diovan patent expires but generic valsartan is MIA. www.forbes.com/sites/larryhusten/2012/09/25/another-one-bites- the-dustdiovan-patent-expires-but-genericvalsartan-is-mia/(accessed 2012 Nov 25).
35. Express Scripts. 2012 drug trend report. www.drugtrendreport.com/ (accessed 2012 Dec 7).
36. Hoffman JM, Shah ND, Vermeulen LC et al. Projecting future drug expenditures- 2009. Am J Health-Syst Pharm. 2009; 66:237-57.
37. Hoffman JM, Doloresco F, Vermeulen LC et al. Projecting future drug expenditures- 2010. Am J Health-Syst Pharm. 2010; 67:919-28.
38. Doloresco F, Fominaya C, Schumock GT et al. Projecting future drug expenditures- 2011. Am J Health-Syst Pharm. 2011; 68:921-32.
39. Hoffman JM, Shah ND, Vermeulen LC et al. Projecting future drug expenditures- 2005. Am J Health-Syst Pharm. 2005; 62:149-67. (Pubitemid 40674546)
40. ASHP guidelines on medication cost management strategies for hospitals and health systems. Am J Health-Syst Pharm. 2008; 65:1368-84.
41. Zellmer WA. Inventing our future. Am J Health-Syst Pharm. 2007; 64:1262. Editorial. (Pubitemid 47216193)
42. Schwartz RN, Eng KJ, Frieze DA et al. NCCN Task Force report: specialty pharmacy. J Natl Compr Canc Netw. 2010; 8(suppl 4):S-1-12.
43. Caselnova 3rd D, Donley K, Ehlers D et al. Report of the ASHP Task Force on Caring for Patients Served by Specialty Suppliers. Am J Health-Syst Pharm. 2010; 67:1650.
44. Zellmer WA, Walling RS. Pharmacy forecast 2013-2017: strategic planning advice for pharmacy departments in hospitals and health systems: executive summary of a trends report from the Center for Health-System Pharmacy Leadership, ASHP Research and Education Foundation. Am J Health-Syst Pharm. 2012; 69: 2083-7.
45. Zelenetz AD, Ahmed I, Braud EL et al. NCCN biosimilars white paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw. 2011; 9(suppl 4):S1-22.
46. Food and Drug Administration. FDA issues draft guidance on biosimilar product development. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm291232.htm (accessed 2013 Jan 17).
47. McCamish M, Woollett G. Worldwide experience with biosimilar development. MAbs. 2011; 3:209-17.
48. Weise M, Bielsky MC, De Smet K et al. Biosimilars: what clinicians should know. Blood. 2012; 120:5111-7.
49. Food and Drug Administration. FDA approves new treatment for severe neutropenia in certain cancer patients. www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm317392.htm (accessed 2012 Dec 17).
50. Traynor K. FDA approves Teva's Tbofilgrastim. www.ashp.org/menu/News/ PharmacyNews/NewsArticle.aspx?Source=News&Type=Rss&Id=3775 (accessed 2012 Dec 17).
51. Hemphill Kraus EJ. A shift on "pay for delay"-reopening doors for pharmaceutical competition? N Engl J Med. 2012; 367:1681-3.
52. FTC seeks U.S. Supreme Court review in AndroGel "pay-for-delay" case. www.ftc.gov/opa/2012/10/androgel.shtm (accessed 2012 Nov 24).